

Daniel E Furst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1368591/publications.pdf>

Version: 2024-02-01

196
papers

12,494
citations

38742

50
h-index

27406

106
g-index

204
all docs

204
docs citations

204
times ranked

11648
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. <i>Rheumatology</i> , 2023, 62, 565-574.	1.9	6
2	New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Chronic Anterior Uveitis. <i>Arthritis Care and Research</i> , 2023, 75, 975-982.	3.4	17
3	Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e192-e192.	0.9	20
4	Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1477-1483.	3.4	1
5	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1385-1395.	1.9	10
6	The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 117-127.	1.7	3
7	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.7	25
8	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Associated Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 674-684.	5.6	57
9	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. <i>Rheumatology</i> , 2022, 61, 4155-4162.	1.9	8
10	Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 649-661.	2.3	1
11	Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1399-1408.	5.6	9
12	Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 435-446.	2.3	4
13	Examination of the Validity of Skin Ultrasound to Quantitate Skin Involvement for Multicenter Clinical Trials in Patients with Systemic Sclerosis (SSc): A Systematic Literature Review (Tj ETQq1 1 @.784314 ogBT /Ov		
14	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. <i>Rheumatology</i> , 2022, 62, 234-242.	1.9	13
15	Predictive model of risk and severity of enteritis in systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 1226-1236.	1.6	5
16	Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique study. <i>Disability and Rehabilitation</i> , 2021, 43, 3339-3346.	1.8	12
17	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249.	0.9	6
18	Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. <i>Clinical Rheumatology</i> , 2021, 40, 2277-2284.	2.2	11

#	ARTICLE	IF	CITATIONS
19	The role of ultrasound in systemic sclerosis: On the cutting edge to foster clinical and research advancement. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 123-132.	1.7	20
20	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021, 23, 51.	3.5	18
21	Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population—a multicentre study. <i>Rheumatology</i> , 2021, 60, 5142-5148.	1.9	11
22	Trend in women representation among authors of high rank rheumatology journals articles, 2002–2019. <i>Rheumatology</i> , 2021, 60, 5127-5133.	1.9	1
23	Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0) to change in scleroderma patients. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 236-241.	1.7	1
24	Pharmacokinetic equivalence of CT-P17 to high concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. <i>Clinical and Translational Science</i> , 2021, 14, 1280-1291.	3.1	11
25	Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 425-429.	3.4	2
26	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4323-4333.	2.4	7
27	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	3.4	7
28	The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. <i>Arthritis Research and Therapy</i> , 2021, 23, 212.	3.5	16
29	Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. <i>BMJ Open</i> , 2021, 11, e049850.	1.9	0
30	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. <i>Arthritis Care and Research</i> , 2021, , .	3.4	3
31	Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. , 2021, 8, 120-129.		5
32	Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 1637-1649.	2.3	16
33	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 10.	3.5	18
34	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 124-133.	0.8	1
35	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 124-133.	0.8	11
36	Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2020, 47, 881-887.	2.0	32

#	ARTICLE	IF	CITATIONS
37	Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 7-11.	3.4	6
38	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
39	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.9	63
40	Evaluation of cognitive function in systemic sclerosis patients: a pilot study. <i>Clinical Rheumatology</i> , 2020, 39, 1551-1559.	2.2	12
41	Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 143-151.	1.7	3
42	Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease. <i>Rheumatology</i> , 2020, 59, 2024-2029.	1.9	21
43	Preliminary study of the association of serum irisin levels with poor sleep quality in rheumatoid arthritis patients. <i>Sleep Medicine</i> , 2020, 67, 71-76.	1.6	14
44	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
45	Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 231-236.	1.7	2
46	Machine learning predicts stem cell transplant response in severe scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1608-1615.	0.9	29
47	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
48	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 963-967.	3.4	3
49	Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 935-944.	2.4	8
50	Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial. <i>Rheumatology and Therapy</i> , 2020, 7, 327-344.	2.3	25
51	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1269-1276.	0.9	3
52	Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 161-168.	0.8	5
53	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1371-1378.	0.9	43
54	Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use. <i>Drug Safety</i> , 2019, 42, 1499-1506.	3.2	9

#	ARTICLE	IF	CITATIONS
55	The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. <i>European Journal of Internal Medicine</i> , 2019, 70, 43-49.	2.2	7
56	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	2.0	11
57	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019, 71, 2059-2067.	5.6	55
58	Targeting inflammatory pathways in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 135.	3.5	27
59	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2019, , .	1.9	0
60	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1173-1178.	2.0	6
61	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. <i>RMD Open</i> , 2019, 5, e000840.	3.8	8
62	Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters. <i>Arthritis Research and Therapy</i> , 2019, 21, 95.	3.5	8
63	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. <i>Journal of Rheumatology</i> , 2019, 46, 1316-1325.	2.0	23
64	Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and management. <i>Clinical Immunology</i> , 2019, 202, 59-75.	3.2	10
65	Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review. <i>Clinical Rheumatology</i> , 2019, 38, 1433-1436.	2.2	4
66	THU0170â€¦A MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM DATA FROM THE OPEN-LABEL TREATMENT PERIOD. , 2019, , .		0
67	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	1.9	16
68	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 122-130.	0.9	141
69	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 603-608.	2.0	16
70	Imaging and serum biomarkers in connective tissue diseaseâ€“associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 573-575.	0.9	9
71	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 958-966.	3.4	9
72	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36

#	ARTICLE	IF	CITATIONS
73	Timely renal transplantation for scleroderma end-stage kidney disease patients can improve outcomes and quality of life. <i>Annals of Translational Medicine</i> , 2019, 7, 60-60.	1.7	5
74	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018, 378, 35-47.	27.0	417
75	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. <i>Clinical Rheumatology</i> , 2018, 37, 2331-2340.	2.2	22
76	Ultrasound characterization of cutaneous ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 1555-1561.	2.2	34
77	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. <i>Arthritis Care and Research</i> , 2018, 70, 439-444.	3.4	53
78	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 644-652.	5.6	77
79	Etiology unknown: Qualitative analysis of patient attributions of causality in scleroderma. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 182-188.	1.7	0
80	Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity. <i>Clinical Rheumatology</i> , 2018, 37, 3239-3246.	2.2	19
81	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 2225-2231.	3.0	4
82	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. <i>Frontiers in Immunology</i> , 2018, 9, 2045.	4.8	67
83	High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference. <i>Arthritis Research and Therapy</i> , 2018, 20, 181.	3.5	40
84	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , 2018, 13, e0189498.	2.5	25
85	Validation of Sonography findings of synovitis and tenosynovitis of hands and wrists in patients with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 228-236.	1.7	2
86	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	1.9	53
87	Examining the validity of the rheumatoid arthritis magnetic resonance imaging score according to the OMERACT filter—a systematic literature review. <i>Rheumatology</i> , 2017, 56, 1177-1188.	1.9	23
88	Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , 2017, 44, 795-798.	2.0	0
89	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	1.9	51
90	High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 403-408.	3.4	17

#	ARTICLE	IF	CITATIONS
91	Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. <i>Clinical Rheumatology</i> , 2017, 36, 2045-2054.	2.2	27
92	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease. <i>Chest</i> , 2017, 151, 813-820.	0.8	54
93	Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. <i>Joint Bone Spine</i> , 2017, 84, 747-748.	1.6	17
94	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , 2017, 56, v12-v16.	1.9	6
95	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. <i>Rheumatology</i> , 2017, 56, v33-v37.	1.9	4
96	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v27-v32.	1.9	23
97	Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v4-v11.	1.9	6
98	Points to consider in renal involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v49-v52.	1.9	12
99	Assessment of skin involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v53-v66.	1.9	41
100	Points to consider Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v45-v48.	1.9	23
101	Points to consider for skin ulcers in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v67-v71.	1.9	59
102	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. <i>Journal of Rheumatology</i> , 2017, 44, 1536-1543.	2.0	25
103	An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1734-1739.	2.0	9
104	Update of sarilumab to treat rheumatoid arthritis based on randomized clinical trials: a systematic review. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 741-752.	3.0	10
105	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1916-1919.	2.0	11
106	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 699-708.	3.4	19
107	Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v17-v22.	1.9	13
108	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. <i>Rheumatology</i> , 2017, 56, v23-v26.	1.9	9

#	ARTICLE	IF	CITATIONS
109	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.7	321
110	Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. <i>International Journal of Rheumatology</i> , 2017, 2017, 1-15.	1.6	24
111	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.7	62
112	Clinical Pearls from the World Congress on Systemic Sclerosis, February, 2016. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 64-68.	1.7	0
113	Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 7-9.	1.7	3
114	Systemic sclerosis trial design moving forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 177-180.	1.7	42
115	Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project. <i>PLoS ONE</i> , 2016, 11, e0147556.	2.5	4
116	Esophageal Surgeries in Systemic sclerosis (SSc) - A Systematic Review of the Literature. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 10-15.	1.7	2
117	Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium. <i>Arthritis and Rheumatology</i> , 2016, 68, 1483-1492.	5.6	90
118	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , 2016, 2, e000225.	3.8	54
119	Wide-field imaging of birefringent synovial fluid crystals using lens-free polarized microscopy for gout diagnosis. <i>Scientific Reports</i> , 2016, 6, 28793.	3.3	42
120	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1501-1505.	0.9	17
121	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	7.4	95
122	Premedication prevents infusion reactions and improves retention rate during infliximab treatment. <i>Clinical Rheumatology</i> , 2016, 35, 2841-2845.	2.2	15
123	Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 312-318.	3.4	28
124	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1-25.	3.4	890
125	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	10.7	754
126	Scleroderma renal crisis and renal involvement in systemic sclerosis. <i>Nature Reviews Nephrology</i> , 2016, 12, 678-691.	9.6	117

#	ARTICLE	IF	CITATIONS
127	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2016, 18, 305.	3.5	58
128	Calcinosis in systemic sclerosis: subsets, distribution and complications. <i>Rheumatology</i> , 2016, 55, 1610-1614.	1.9	35
129	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	3.5	18
130	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 374-381.	0.9	76
131	Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. <i>Rheumatology</i> , 2016, 55, 669-679.	1.9	62
132	The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2016, 43, 512-523.	2.0	50
133	Modified intention-to-treat analysis did not bias trial results. <i>Journal of Clinical Epidemiology</i> , 2016, 72, 66-74.	5.0	39
134	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 439-445.	3.4	23
135	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. <i>Journal of Rheumatology</i> , 2015, 42, 2185-2189.	2.0	40
136	Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. <i>Rheumatology (Sunnyvale, Calif)</i> , 2015, 05, .	0.3	11
137	Management of Systemic Sclerosis-Related Skin Disease. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 399-417.	1.9	17
138	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 1369-1379.	1.9	21
139	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 372.	3.5	87
140	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 19-26.	0.9	201
141	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015, 54, 144-151.	1.9	30
142	Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , 2015, 42, 1624-1630.	2.0	17
143	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	3.4	60
144	Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. <i>Rheumatology</i> , 2015, 54, kev249.	1.9	10

#	ARTICLE	IF	CITATIONS
145	Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. <i>Journal of Rheumatology</i> , 2015, 42, 1761-1766.	2.0	194
146	Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. <i>PLoS ONE</i> , 2015, 10, e0136982.	2.5	7
147	What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S117-22.	0.8	7
148	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1607-1615.	0.9	125
149	Rheumatoid Arthritis: Are Current Research-based Guidelines Clinically Relevant?. <i>Journal of Rheumatology</i> , 2014, 41, 1569-1570.	2.0	2
150	Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. <i>BMJ Open</i> , 2014, 4, e005297-e005297.	1.9	19
151	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 55-62.	3.4	69
152	Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. <i>Rheumatology</i> , 2014, 53, 1560-1569.	1.9	178
153	Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1781-1787.	0.9	21
154	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
155	Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 458-469.	3.4	81
156	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 666-672.	3.4	115
157	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
158	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Rheumatology</i> , 2013, 52, 1845-1855.	1.9	28
159	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
160	Medical costs and health care resource use in patients with inflammatory myopathies in an insured population. <i>Muscle and Nerve</i> , 2012, 46, 496-505.	2.2	17
161	Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. <i>Muscle and Nerve</i> , 2012, 45, 676-683.	2.2	127
162	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.9	394

#	ARTICLE	IF	CITATIONS
163	Adverse Events during the Scleroderma Lung Study. American Journal of Medicine, 2011, 124, 459-467.	1.5	30
164	Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care and Research, 2011, 63, 856-864.	3.4	49
165	Rheumatoid arthritis and pregnancy: Disease activity, pregnancy outcomes, and treatment options during pregnancy and lactation. Drug Development Research, 2011, 72, 689-702.	2.9	3
166	Double-Blind, Randomized, Controlled, Pilot Study Comparing Classic Ayurvedic Medicine, Methotrexate, and Their Combination in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2011, 17, 185-192.	0.9	63
167	Rituximab for Rheumatoid Arthritis: A Meta-Analysis and Systematic Review. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S5566.	0.4	1
168	Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2010, 28, S5-12.	0.8	19
169	Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo. Chest, 2009, 136, 1333-1340.	0.8	127
170	High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease. Chest, 2008, 134, 358-367.	0.8	198
171	Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases, 2007, 66, 893-899.	0.9	96
172	Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection. Seminars in Arthritis and Rheumatism, 2006, 36, 159-167.	3.4	207
173	Tacrolimus in Patients with Rheumatoid Arthritis. Drugs, 2005, 65, 1002-1003.	10.9	0
174	A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 2303-10.	2.0	12
175	Relationships of Positive and Negative Affect to Coping and Functional Outcomes in Systemic Sclerosis. Cognitive Therapy and Research, 2004, 28, 593-610.	1.9	14
176	Anakinra: Review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Clinical Therapeutics, 2004, 26, 1960-1975.	2.5	155
177	Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety) Tj ETQq1 1 0.784314 rgt3/5 overlo	0.78	114
178	Stem cell transplantation for autoimmune disease: progress and problems. Current Opinion in Rheumatology, 2002, 14, 220-224.	4.3	20
179	Disease-Modifying Antirheumatic Drugs. Drugs and Aging, 1995, 7, 420-437.	2.7	28
180	Are There Differences Among Nonsteroidal Antiinflammatory Drugs?. Arthritis and Rheumatism, 1994, 37, 1-9.	6.7	111

#	ARTICLE	IF	CITATIONS
181	Abnormalities of Renal Physiology in Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 1994, 37, 67-74.	6.7	45
182	Antirheumatic drugs: A proposed new classification. <i>Arthritis and Rheumatism</i> , 1993, 36, 336-339.	6.7	66
183	Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 1988, 9, 273-283.	1.9	9
184	Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1985, 28, 308-314.	6.7	42
185	Low-Dose D-Penicillamine Therapy in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 1983, 26, 581-592.	6.7	91
186	Comparison of Tolmetin Kinetics in Rheumatoid Arthritis and Matched Healthy Controls. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 557-562.	2.0	2
187	Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 371-377.	4.7	35
188	Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 733-740.	4.7	91
189	Effects of Indomethacin and Carprofen on Renal Homeostasis in Rheumatoid Arthritis Patients and in Healthy Individuals. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 493-500.	2.0	10
190	The arthropathy of advanced progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1981, 24, 874-884.	6.7	78
191	Abnormalities of Pulmonary Vascular Dynamics and Inflammation In Early Progressive Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 1981, 24, 1403-1408.	6.7	72
192	Steady-state serum salicylate levels in hospitalized patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1979, 22, 384-388.	6.7	27
193	A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. <i>Arthritis and Rheumatism</i> , 1979, 22, 904-910.	6.7	111
194	Salicylate clearance, the resultant of protein binding and metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 380-389.	4.7	74
195	Association of HLA Antigen A9 with Progressive Systemic Sclerosis (Scleroderma). <i>Tissue Antigens</i> , 1978, 11, 357-361.	1.0	40
196	Muscle disease in progressive systemic sclerosis. diagnostic and therapeutic considerations. <i>Arthritis and Rheumatism</i> , 1978, 21, 62-71.	6.7	170